Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology

The success of immunotherapy using immune checkpoint inhibitors has changed the practice of cancer treatment tremendously. However, there are still many clinical challenges, such as drug resistance, predictive biomarker development, exploration of combination therapies, and prediction of immune-rela...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2020-05, Vol.25 (5), p.831-841
Main Authors: Saito, Ryoichi, Kobayashi, Takashi, Kashima, Soki, Matsumoto, Keiyu, Ogawa, Osamu
Format: Article
Language:English
Subjects:
Animal models
Cancer immunotherapy
Cancer Research
Cell culture
Drug resistance
Immune checkpoint inhibitors
Immunotherapy
Invited Review Article
Medicine
Medicine & Public Health
Oncology
Surgical Oncology
Translation
Tumor cell lines
Xenografts
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The success of immunotherapy using immune checkpoint inhibitors has changed the practice of cancer treatment tremendously. However, there are still many clinical challenges, such as drug resistance, predictive biomarker development, exploration of combination therapies, and prediction of immune-related adverse events in preclinical settings. To overcome these problems, it is essential to establish faithful preclinical mouse models that recapitulate the clinical features, molecular genetics, biological heterogeneity, and immune microenvironment of human cancers. Here we review the advantages and disadvantages of current preclinical mouse models, including syngeneic murine tumor cell lines, autochthonous tumor models, cancer cell line-derived xenografts, patient-derived-xenografts, and various kinds of immunologically humanized mice. We discuss how these models should be characterized and applied in preclinical settings, and how we should prepare preclinical studies for successful translation from bench to bedside.
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-019-01520-z